In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis - Study in healthy subjects and correlation with blood fibrinolytic parameters

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 725-729

  Colucci, Mario ^a,b   Scopece, Silvia ^a   Gelato, Antonio V ^a   Dimonte, Donato ^a   Semeraro, Nicola ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; ANTIBODY; FIBRINOGEN; FIBRINOLYTIC AGENT; IODINE 125; LIPOPROTEIN A; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; BLOOD CLOT RETRACTION; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBUS;

EID: 0030994826     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656041     Document Type: Article

References (19)

1. Verstraete M. Advances in thrombolytic therapy. Cardiovasc Drug Therapy 1992; 6: 111-24.
2. Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-6.
3. Musselman DR, Tate DA. Oberhardt BJ, Abruzzini AF, Blauwet MB, Koch G, Dehmer GJ. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase). Am J Cardiol 1994; 73: 544-9.
4. Colucci M, Cavallo LG, Agnelli G, Mele A, Burgi R, Heim J, Semeraro N. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Thromb Haemost 1993; 69: 466-72.
5. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): Conditions and therapeutic targets. Fibrinolysis 1994; 8 (suppl 2): 1-7.
6. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-5.
7. Erickson LA, Ginsburg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
8. Onundarson PT, Francis CW, Marder VJ. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1992; 120: 120-8.
9. Juhan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EKO. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost 1987; 58: 1096.
10. Eriksson E, Tengborn L, Risberg B. The effect of various anticoagulant/antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 1989; 61: 511-6.
11. Coller H. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
12. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb 1994; 14: 1452-8.
13. Robbie LA, Bennet B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33.
14. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65: 275-9.
15. Barbash JI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of infarct artery after thrombolysis in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-5.
16. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995; 91: 1341-6.
17. Blann AD. A reliable marker of endothelial cell dysfuntion: does it exist? Br J Haematol 1995; 90: 244-8.
18. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, Boisseau M. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12: 355-9.
19. Colucci M, Gelato AV, Scopece SM, Altomare DF, Rinaldi M, Semeraro N. Resistance to fibrinolysis in patients with obstructive jaundice. Fibrinolysis 1996; 10 (suppl 3): 49 (Abstract).